Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Type 2 Diabetes and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GCK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GCK Recombinant Protein (WT & MODY Mutants) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Active Enzyme. |
View GCK Products |
| Gene Delivery | GCK Lentivirus / Promise-ORF Full-length ORF for stable cell lines (e.g., hepatocyte or beta-cell models). |
View GCK Products |
| Research Tool | Anti-GCK Antibody Rabbit polyclonal / mouse mAb for Western/ELISA. Immunogen sequence verified. |
View GCK Products |
| Validator | GCK siRNA Set For knockdown verification in glucose-stimulated insulin secretion assays. |
View GCK Products |
| Related Target: HK1 | HK1 (Hexokinase 1) Off-target liability counter-screening for GCK activator selectivity. |
View HK1 Products |
| Related Target: GLP1R | GLP1R Synergistic T2D pathway partner for combination therapy studies. |
View GLP1R Products |
| Related Target: SLC2A2 | SLC2A2 (GLUT2) Beta-cell glucose transport synergy in metabolic disease. |
View SLC2A2 Products |
| Related Target: INSR | INSR Downstream insulin signaling cascade evaluation. |
View INSR Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isozyme Selectivity (vs HK1/2/3) | Human Hexokinase homolog panel available (>95% purity), strictly sequence verified by mass spec. |
| MODY2 / CHI Mutant Profiling | MODY2 mutant protein library (key inactivating mutations) sequence verified for mechanistic safety studies. |
| Cell-based Assay Sensitivity | Endotoxin <1 EU/µg, suitable for sensitive insulin secretion and glucose uptake assays. |
| Enzyme Kinetic Validation | High-purity (>95%) recombinant GCK for accurate Vmax and Km determination. |
| Allosteric Modulator Screening | Properly folded, functional proteins enabling sensitive compound screening. |
| Lack of Reliable Controls | Sequence-verified wild-type and mutant variants available for rigorous baselining. |
| False Positives / Off-target | Validated GCK siRNA included for specificity checks in cellular assays and target engagement proof. |
GCK Structure and Functional Domains
GCK (Glucokinase) contains two distinct hexokinase domains: an N-terminal domain and a C-terminal domain (UniProt A0A5F9ZGW4). These domains contribute to its allosteric regulation and catalytic activity as a glucose sensor. Understanding these domains is critical for designing selective allosteric activators and for profiling MODY2 mutations that often reside in these regions.
Live GCK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GCK-targeted therapeutics has shifted from first-generation pan-activators toward precision metabolic modulation. Following the 2022 approval of Hua Medicine's dorzagliatin in China, the field validated glucokinase activation as a viable mechanism for Type 2 diabetes. Earlier programs by Pfizer, Roche, and Merck were largely discontinued due to hypoglycemia and hepatic steatosis risks, underscoring the need for refined allosteric mechanisms and tissue-selective profiles. The current R&D wave focuses on liver-selective or dual-acting physiological modulators. Next-generation strategies are heavily leaning toward combination regimens with GLP-1 receptor agonists and SGLT2 inhibitors, as well as mutant-specific profiling to address MODY2 and congenital hyperinsulinism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric Activator) | Hua Medicine, vTv Therapeutics, Pegbio, Ventyx | Type 2 Diabetes, MODY2 | HTS Enzymatic Assay (Need high-purity WT GCK, endotoxin-free) |
| Isozyme Selectivity Panel | All GCKA developers | Safety / Off-target liability | Counter-screen against HK1/HK2/HK3 (Need homolog panel proteins) |
| Combination Therapies | Various Big Pharma | Metabolic Syndrome, T2D | Pathway Cross-Talk (Need GLP1R/INSR/SLC2A2 reagents) |
| Gene Therapy / Editing | Emerging Biotech | Severe Monogenic Diabetes | Expression Validation (Need specific Anti-GCK Abs) |